AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 295: H2436-H2446, 2008. First published October 17, 2008; doi:10.1152/ajpheart.00690.2008
0363-6135/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/6/H2436    most recent
00690.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Ye, Y.
Right arrow Articles by Birnbaum, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ye, Y.
Right arrow Articles by Birnbaum, Y.

Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice

Yumei Ye,1,2 Yu Lin,1 Saraswathy Manickavasagam,1 J. Regino Perez-Polo,2 Brian C. Tieu,3 and Yochai Birnbaum1,2

1Division of Cardiology, 2Department of Biochemistry and Molecular Biology, and 3Graduate School of Biomedical Science, University of Texas Medical Branch, Galveston, Texas

Submitted 3 July 2008 ; accepted in final form 14 October 2008

Endothelial nitric oxide synthase (eNOS) activation with subsequent inducible NOS (iNOS), cytosolic phospholipase A2 (cPLA2), and cyclooxygenase-2 (COX2) activation is essential to statin inhibition of myocardial infarct size (IS). In the rat, the peroxisome proliferator-activated receptor-{gamma} agonist pioglitazone (Pio) limits IS, upregulates and activates cPLA2 and COX2, and increases myocardial 6-keto-PGF1{alpha} levels without activating eNOS and iNOS. We asked whether Pio also limits IS in eNOS–/– and iNOS–/– mice. Male C57BL/6 wild-type (WT), eNOS–/–, and iNOS–/– mice received 10 mg·kg–1·day–1 Pio (Pio+) or water alone (Pio–) for 3 days. Mice underwent 30 min coronary artery occlusion and 4 h reperfusion, or hearts were harvested and subjected to ELISA and immunoblotting. As a result, Pio reduced IS in the WT (15.4 ± 1.4% vs. 39.0 ± 1.1%; P < 0.001), as well as in the eNOS–/– (32.0 ± 1.6% vs. 44.2 ± 1.9%; P < 0.001) and iNOS–/– (18.0 ± 1.2% vs. 45.5 ± 2.3%; P < 0.001) mice. The protective effect of Pio in eNOS–/– mice was smaller than in the WT (P < 0.001) and iNOS–/– (P < 0.001) mice. Pio increased myocardial Ser633 and Ser1177 phosphorylated eNOS levels in the WT and iNOS–/– mice. iNOS was undetectable in all six groups. Pio increased cPLA2, COX2, and PGI2 synthase levels in the WT, as well as in the eNOS–/– and iNOS–/–, mice. Pio increased the myocardial 6-keto-PGF1{alpha} levels and cPLA2 and COX2 activity in the WT, eNOS–/–, and iNOS–/– mice. In conclusion, the myocardial protective effect of Pio is iNOS independent and may be only partially dependent on eNOS. Because eNOS activity decreases with age, diabetes, and advanced atherosclerosis, this effect may be relevant in a clinical setting and should be further characterized.

endothelial nitric oxide synthase; inducible nitric oxide synthase; peroxisome proliferator-activated receptor-{gamma}



Address for reprint requests and other correspondence: Y. Birnbaum, Sec. of Cardiology, Baylor College of Medicine, 1709 Dryden Rd., Ste. 9.32, MS: BCM 620, Houston, TX 77030 (e-mail: ybirnbau{at}bcm.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.